HIMS Sees Accelerating Growth In Q2
Aug 6, 2024
Another excellent report from HIMS, which has been one of our best-performing stocks this year. Revenue growth accelerated to 52% in Q2, up from 46% in Q1, as the launch of GLP-1 weight loss drugs and continued momentum in its other categories drew users to the platform. Subscribers were up an impressive 43% year-over-year. Management continues to see opportunities in expanding its existing offerings as well as adding new health verticals. HIMS is still a great growth stock, but the market has caught up to the value somewhat. It still looks attractive at current prices. I'm raising the fair value from $17 up to $21 per share.
Follow @GreenDotStocks
Information contained on this website represents only the opinions of the author and should not be used as the sole basis for investing decisions. By using this site, you agree to all statements in the Site Policy.
Watch List
| S | 9.41% |
| CRWD | 73.34% |
| SEMR | -15.86% |
| SNOW | 15.48% |
| TSM | -1.89% |
vs. Fair Value Estimates
Buy List
| GOOG | -33.69% |
| NYAX | -61.69% |
| ASR | -31.25% |
| PAYC | -28.54% |
| HRMY | -49.59% |
| YOU | -45.59% |
| MELI | -30.27% |
| ADBE | -30.99% |
vs. Fair Value Estimates
Hold List
| MSFT | -21.19% |
| ODD | -23.90% |
| FLYW | 4.57% |
| CELH | -15.59% |
| TOST | 31.86% |
| CPNG | -2.38% |
| HIMS | -6.43% |
| MNDY | 15.47% |
| GLBE | 16.55% |
| ZS | 18.59% |
| V | -11.99% |
| ADSK | 11.66% |
| NOW | 50.93% |
| ABNB | -19.63% |
| FTNT | 4.51% |
| TEAM | 14.85% |
vs. Fair Value Estimates